| Help | About | Contact Us

Publication : Computationally restoring the potency of a clinical antibody against Omicron.

First Author	Desautels TA	Year	2024
Journal	Nature	Volume	629
Issue	8013	Pages	878-885
PubMed ID	38720086	Mgi Jnum	J:349982
Mgi Id	MGI:7660463	Doi	10.1038/s41586-024-07385-1
Citation	Desautels TA, et al. (2024) Computationally restoring the potency of a clinical antibody against Omicron. Nature 629(8013):878-885

abstractText

The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs(1-3) and revealed how quickly viral escape can curtail effective options(4,5). When the SARS-CoV-2 Omicron variant emerged in 2021, many antibody drug products lost potency, including Evusheld and its constituent, cilgavimab(4-6). Cilgavimab, like its progenitor COV2-2130, is a class 3 antibody that is compatible with other antibodies in combination(4) and is challenging to replace with existing approaches. Rapidly modifying such high-value antibodies to restore efficacy against emerging variants is a compelling mitigation strategy. We sought to redesign and renew the efficacy of COV2-2130 against Omicron BA.1 and BA.1.1 strains while maintaining efficacy against the dominant Delta variant. Here we show that our computationally redesigned antibody, 2130-1-0114-112, achieves this objective, simultaneously increases neutralization potency against Delta and subsequent variants of concern, and provides protection in vivo against the strains tested: WA1/2020, BA.1.1 and BA.5. Deep mutational scanning of tens of thousands of pseudovirus variants reveals that 2130-1-0114-112 improves broad potency without increasing escape liabilities. Our results suggest that computational approaches can optimize an antibody to target multiple escape variants, while simultaneously enriching potency. Our computational approach does not require experimental iterations or pre-existing binding data, thus enabling rapid response strategies to address escape variants or lessen escape vulnerabilities.

Expression

Publication --> Expression annotations

Other

44 Authors

4 Bio Entities

Trail: Publication

0 Expression

Questions? Comments? Click here!

MouseMine is a collaboration between MGI at The Jackson Laboratory and the InterMine project at the Cambridge Systems Biology Centre. MouseMine is funded through a grant from the NIH/NHGRI.The Jackson Laboratory makes no representation about the suitability or accuracy of this software or data for any purpose, and makes no warranties, either express or implied, including merchantability and fitness for a particular purpose or that the use of this software or data will not infringe any third party patents, copyrights, trademarks, or other rights. the software and data are provided "as is". This software and data are provided to enhance knowledge and encourage progress in the scientific community and are to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of the Jackson Laboratory.

Your name:
Your email address:
Subject:
Message:	---- Current page: ---- /mousemine/report.do?id=76675580&trail=%7C76675580

MouseMine